What I Paid for GLP-1 vs. What I Expected (Read the Fine Print)

The number on the ad was not the number I paid

I clicked the ad with the jaw-dropping low monthly price the way every mom on a budget clicks it — hoping it was real. And for one month it sort of was. Then the fine print unfolded, and by month three my card was being charged something I had never planned for. That gap between what I expected and what I actually paid is the whole reason I wrote this down.

The boundary I hold: I am a mom who walked these funnels and pays for this medication, not a clinician. This is education from published trial data and the FDA labels, not medical advice.

Teaser rates and the asterisk economy

The price that got me in the door was an introductory rate, and the asterisk was doing a lot of quiet work. Once I started reading the public pricing pages properly instead of the ad, I kept finding the same three patterns: the low number applied only to the lowest starter dose, or only if you prepaid a multi-month bundle, or it stepped up at month two when the new-patient pricing lapsed.

None of that is necessarily a scam. But it changed the question I ask. I stopped asking what the intro price is and started asking what month three and month six cost at the dose I'll actually be on — because titration walks you up over weeks, and on some pricing models a higher dose means a higher bill. The sticker that assumes I'll sit at the starter dose forever was quietly optimistic about me.

Two patterns I now look for first, because they're the ones that got me. A second bill sitting beside the price. Alloy advertises compounded semaglutide "starting at $70" and charges a mandatory $99 a month on top, so the real floor is $169 — printed right there, and I still nearly missed it. A price that climbs with your dose. Midi Health publishes its whole ladder, which I respect, and it goes from $165.90 at the starting dose to $355 at the top. Neither is hiding anything, but both would have blown my budget at the first number.

Two more patterns now. The prepay tier that's never on the default sticker. MadeMed's $239/mo quarterly plan — shown by default as "Most Popular" — quietly drops to $199/mo on six months instead, only visible once you click past the default tier. The cancellation policy buried far from the price. Peter MD prices its GLP-1 combo reasonably, but its refund policy makes all sales final once medication ships, and canceling auto-renewal means emailing support 48 hours ahead — miss that window and you're charged again. I read the cancellation page first now. A "starting at" price that only holds on the longest plan. HealthOn advertises "starting at $189" — real, but only on a 12-month prepay; month-to-month isn't published anywhere I found. HealthiCare does a version of it. A promo that hides the real number in plain sight. Cielo labels both: "Reg $199/Month" beside "From $89/Month*," a 6-month commitment. MyFastRx stacks a coupon on a standard rate on prepay tiers — disclosed, but worth a calculator.

Compounded vs. brand, and why the price gap exists

Most of the shockingly low numbers I'd been comparing were for compounded semaglutide or tirzepatide, not the brand-name pens. That's a real category with real savings, but it's a different product story — availability, formulation and oversight can differ, and pricing shifts with supply. I had been holding a compounded monthly price next to a brand price and calling it a comparison, which is apples to oranges. Now I ask on the intake exactly what medication the quoted price covers, and I'd tell a friend to do the same before her card is in.

The line item nobody put on the pricing page: stopping

This is the one that blindsided me, and it belongs in a cost article even though it sounds like a clinical one. These medicines manage weight while you take them — they aren't a one-and-done course. When people stopped semaglutide in the STEP 1 trial extension, they regained a large share of the lost weight over the following year¹, and the controlled STEP 4 trial showed that people who switched to placebo regained while those who continued kept losing². Tirzepatide's SURMOUNT-4 told the same story — stopping led to substantial regain, continuing maintained the loss³.

Reading that reframed my whole budget. I had been treating this like a three-month splurge, roughly the way I treat a gym contract in January. It isn't. The price that mattered was the sustainable monthly one I could carry for a year and more, not the thrilling intro rate I'd resent by spring.

What I actually value now

After clicking through a lot of these funnels, the thing I care about most is legible pricing: a clear monthly number, shown before I hand over my medical history, that doesn't detonate at month two. That transparency is a big part of why CoreAge Rx sits at the top of our list — I could do the year-long math before committing instead of after. I walk that flow step by step in what the CoreAge Rx intake actually asks. And if the sticker is the whole decision, the way it was for me at first, I ranked them by price in the cheapest GLP-1, honestly.

A flat, upfront number isn't automatically the cheapest first month — it's usually the honest one, and honest is what let me plan. So line up the sustainable monthly cost at your likely maintenance dose, confirm whether it's compounded or brand, and ask your own clinician what dose you're realistically heading toward, because that's the number your budget has to survive.

The version of me who clicked that ad thought she was buying a season. I was actually signing up for a standing line in the family budget, somewhere between the car insurance and the groceries, and I wish someone had said that out loud first.